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The mammary epithelium is a dynamic, highly
hormone-responsive tissue. To explore chromatin
modifications underlying its lineage specification and
hormone responsiveness, we determined genome-
wide histonemethylation profiles ofmammary epithe-
lial subpopulations in different states. The marked
differences in H3K27 trimethylation between subpop-
ulations in the adult gland suggest that epithelial
cell-fate decisions are orchestrated by polycomb-
complex-mediated repression.Remarkably, themam-
maryepigenomeunderwenthighly specificchanges in
different hormonal contexts, with a profound change
being observed in the global H3K27me3 map of
luminal cells during pregnancy. We therefore exam-
ined the role of the key H3K27 methyltransferase
Ezh2 in mammary physiology. Its expression and
phosphorylation coincided with H3K27me3 modifica-
tions and peaked during pregnancy, driven in part
by progesterone. Targeted deletion of Ezh2 impaired
alveologenesis during pregnancy, preventing lacta-
tion, and drastically reduced stem/progenitor cell
numbers. Taken together, these findings reveal that
Ezh2 couples hormonal stimuli to epigenetic changes
that underpin progenitor activity, lineage specificity,
and alveolar expansion in the mammary gland.INTRODUCTION
The mammary gland, which comprises a branching ductal epi-
thelial network embedded in an adipose-rich stromal matrix,Cis remarkably adaptive to physiological requirements and
undergoes dramatic morphological changes during puberty
and pregnancy. At birth, it manifests as a rudimentary branched
structure, but ductal elongation and branching commence with
puberty and pregnancy provokes the rapid expansion of alveolar
units that differentiate into milk-secretory cells prior to parturi-
tion. The steroid hormones estrogen and progesterone exert
pivotal roles during mammary development via their cognate
receptors, the estrogen receptor (ER) and progesterone receptor
(PR) (Brisken and O’Malley, 2010). ER is essential for ductal
morphogenesis in puberty (Mallepell et al., 2006; Mueller et al.,
2002), whereas PR governs ductal side-branching and alveolar
development during pregnancy (Brisken et al., 1998; Lydon
et al., 1995; Mulac-Jericevic et al., 2003).
The mammary epithelium can be divided into two primary line-
ages: themyoepithelial lineage constitutes the outer layer of cells
that contact the basement membrane, whereas the luminal
lineage comprises both ductal and alveolar cells. Adult stem
cells prospectively isolated from the mouse mammary gland
display the requisite stem cell properties of multilineage differen-
tiation and self-renewal (Shackleton et al., 2006; Stingl et al.,
2006). A recent study has added a new layer of complexity to
the prevailingmodel of themammary epithelial hierarchy through
the identification of unipotent cells that contribute to homeo-
stasis of the gland (Van Keymeulen et al., 2011). It is not yet clear
whether these correspond to stem or progenitor cells and what
their relationship is to the prospectively isolated epithelial sub-
sets. In the mouse, mammary stem cells (MaSCs) have been
shown to be highly responsive to steroid hormones (Asselin-
Labat et al., 2010; Joshi et al., 2010), while progesterone
augmented the number of human bipotent stem-like cells in
cellular assays (Graham et al., 2009). MaSCs lie at the apex of
the hierarchy and give rise to progenitors and mature cells
through progressive restriction. Two distinct types of luminal
progenitor cells have been isolated from the mouse mammaryell Reports 3, 411–426, February 21, 2013 ª2013 The Authors 411
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Figure 1. Histone Methylation Profiles of Mammary Epithelial Subpopulations in the ‘‘Steady State’’ and Their Correlation with Gene
Expression Changes
(A) Genome-wide heat map showing the pattern of H3K4me3, H3K9me2, and H3K27me3marks in MaSC-enriched cells from 5 kb upstream to 5 kb downstream
of the TSS of each gene. Rows correspond to genes clustered by coverage pattern. All 26,310 genes in themm9 genome are shown. The first three columns show
(legend continued on next page)
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gland, but committed basal progenitor cells remain elusive (As-
selin-Labat et al., 2007, 2011; Sleeman et al., 2007).
Although a number of transcription factors and pathways have
been implicated in controlling specific steps along the mammary
differentiation hierarchy (reviewed in Visvader, 2009), the role of
the epigenome in regulating cell-fate decisions and differentia-
tion within this epithelial compartment remains unclear. In other
systems, there is substantial evidence that histone methylation
governs lineage-specific developmental programs and that its
deregulation leads to oncogenesis (Bracken and Helin, 2009;
Sauvageau and Sauvageau, 2010). It is thought that histone
modifications establish discrete domains of active and inactive
chromatin to effect gene expression. Histone lysine methylation
can serve as either an active or repressive mark: trithorax-medi-
ated methylation of lysine 4 on histone H3 within nucleosomes is
associated with activated gene expression, while methylation of
lysine 27 by polycomb group (PcG) proteins is linked with gene
repression and chromatin condensation (Margueron and Rein-
berg, 2011). Ezh2, a member of the PcG family, is a histone
methyltransferase that forms the catalytic component of the
polycomb repressive complex PRC2. This complex silences
lineage specification genes to regulate the maintenance and
differentiation of embryonic and adult stem cells (reviewed in
Margueron and Reinberg, 2011). In embryonic stem cells, where
genome-wide histone methylation patterns have been exten-
sively studied, key developmental genes often exhibit both
repressive H3K27me3 marks and activating H3K4me3 marks
(Bernstein et al., 2006). This bivalent modification has been
proposed tomaintain these genes ‘‘poised’’ for subsequent acti-
vation or repression upon lineage specification. In vivo mapping
studies indicate that PcG-dependent H3K27me3 selectively
marks genes in the epidermal lineages and controls gene ex-
pression changes during the differentiation of skin stem cells
(Lien et al., 2011).
In this report, we examine the contribution of epigenetic mech-
anisms to regulation of the lineage hierarchy in the steady-state
mammary gland and in response to different hormonal milieu.
We determined genome-wide histone methylation profiles of
the MaSC-enriched, luminal progenitor, and mature luminal
subsets. Correlating the global H3K4me3 and H3K27me3 modi-
fication maps with gene expression signatures indicated that
the epigenome has an important role in directing cell-fate
changes from the basal to luminal cell lineage. Moreover, the
mammary epigenome was found to be highly sensitive to dif-
ferent hormonal environments. H3K27 trimethylation of chro-
matin emerged as a key mediator of gene expression changes
during pregnancy, concomitant with high levels of Ezh2, appar-coverage depth on a linear color scale, with the x axis showing distance from the T
In this case, the x axis shows the scale from 4 (nonexpressed) to 12 (maximum
ordered by expression level: the fifth gene group shows little histone marking o
H3K4me3 and increasing H3K27me3 levels. Genes are sorted by expression wit
(B) Segmented bar graphs showing genome-wide percentage of genes with histon
marks in the TSS region are shown, but virtually identical data were obtained for
(C) Heatmaps of gene expression and histone modification changes as cells res
mature luminal (ML) cells. Columns give log2-fold changes for differential gene e
H3K27me3 marking across the broad gene, respectively, for the 200 most differ
See also Figure S1 and Table S1.
Cently activated by phosphorylation. Targeted deletion of Ezh2 in
the mammary epithelium dramatically reduced both ductal and
alveolar morphogenesis. The expression of Ezh2 and its phos-
phorylation appear to be coordinated through progesterone,
a key pregnancy hormone. Thus, hormonally driven expansion
of the alveolar compartment is programmed, at least in part,
by Ezh2-mediated changes in chromatin modification. Given
the critical importance of both progesterone and EZH2 to breast
cancer, these data implicate progesterone-induced global
changes in chromatin structure in the genesis of this disease.
RESULTS
Histone Methylation Landscapes of Mammary Epithelial
Subpopulations in the ‘‘Steady State’’
To explore the relevance of histone modification to the regula-
tion of gene expression along the mammary differentiation hier-
archy, chromatin immunoprecipitation sequencing (ChIP-seq)
was performed on distinct epithelial populations that have
been prospectively isolated from the mouse mammary gland.
These correspond to MaSC-enriched (CD29hiCD24+), com-
mitted luminal progenitor (CD29loCD24+CD61+), and mature
luminal cells (CD29loCD24+CD61) (Asselin-Labat et al., 2007;
Shackleton et al., 2006), all readily isolated from FVB/N glands.
The MaSC-enriched population also contains mature myoepi-
thelial cells and likely basal progenitor cells and is referred to
as the MaSC/basal subset from here on. To avoid changes
that are known to occur in epithelial cells during cell culture,
freshly sorted subsets (approximately 250,000 cells) isolated
from young adult females were used for ChIP. No preamplifica-
tion step was incorporated prior to library preparation in order
to avoid potential bias. High-resolution genome-wide maps
were determined for H3K4me3, H3K27me3, and H3K9me2
modifications. Between 17 and 40 million DNA fragments were
sequenced for each ChIP or input sample using 35 bp paired-
end reads (Table S1).
The overall pattern of histone methylation marking was exam-
ined using heatmaps (Figure 1A and Figure S1A) and density
plots (Figure S1B) of fragment coverage. H3K4me3 occupancy
typically peaked sharply around the transcriptional start site
(TSS) of each gene, whereas the repressive H3K9me2 and
H3K27me3 marks were more evenly spread over the promoter
region and gene body, although with weaker peaks and troughs
still discernible around the TSS. In the MaSC/basal subset,
genes could be clustered into five broad groups by the level
of H3K4me3 marking, from very high to very low (Figure 1A).
Apart from the fifth cluster, lacking any of the marks, the otherSS. The far right column shows log2-normalized expression for the same genes.
expression). Genes are clustered into five groups by their histone pattern and
r expression, while the other four groups correspond roughly to decreasing
hin each cluster, so the right panel appears as an increasing curve.
e methylationmarks in each epithelial subset (FDR < 0.05). Percent H3K27me3
H3K27me3 marks across the gene body plus the TSS.
trict from the MaSC/basal to luminal progenitor (LP) cells and from the LP to
xpression (DE), H3K4me3 marking, H3K27me3 marking in the TSS region, and
entially expressed genes.
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four clusters showed an inverse pattern of H3K4me3 and
H3K27me3 marking. H3K9me2 occupancy was relatively inde-
pendent of H3K4me3 and H3K27me3 status. The luminal pro-
genitor and mature luminal cell populations exhibited similar
patterns (Figure S1A).
H3K4me3 and H3K27me3 but Not H3K9me2 Correlate
with Overall Gene Expression
Next, we related the histone methylation patterns to our previ-
ously published microarray gene expression profiles for the
same cell subpopulations (Lim et al., 2010). Expression level is
shown in the right-most panel of each heatmap, with genes
sorted from high to low expression within each cluster (Figures
1A and S1A). While all the clusters contain genes with a range
of expression levels, average expression strongly increased
with H3K4me3 coverage and decreased with H3K27me3
coverage (Figure 1A). This held for all cell subpopulations (Fig-
ure S1A). While H3K27me3 marks were distributed across the
whole promoter region and gene body, gene expression was
especially sensitive to coverage just upstream and downstream
of the TSS, with low expressed genes showing a trough in
H3K27me3 coverage around the TSS relative to the gene body
and highly expressed genes showing a downstream peak (Fig-
ure S1B). Unlike the other two histone marks, H3K9me2 showed
no overall correlation with expression and was equally associ-
ated with both high and low expression.
To assess enrichment for each histone mark statistically,
we recorded the number of fragments mapping within 3 kb
upstream to 2 kb downstream of the TSS of each gene. For
H3K27me3, the number of fragments mapping to a broad region
comprising the TSS and the entire genomic span of the gene
were recorded. For each cell sample and each histone mark,
enrichment was assessed using a statistical model that treats
the input fragment count profile as representative of nonenriched
genes. Most genes were significantly marked by at least one of
the three modifications (Figure 1B). Interestingly, the number of
genes showing enriched H3K27me3 occupancy at the TSS
increased upon luminal lineage specification (21%, 32%, and
34% in the MaSC/basal, luminal progenitor, and mature luminal
subsets, respectively). Moreover, bivalent marking at the TSS
increased upon basal to luminal cell commitment (10% and
22% in the MaSC/basal and luminal progenitor subsets). As
the MaSC subset remains heterogeneous, it is not clear whether
bivalency plays a role in these adult stem cells.
Expression Changes Correlate with HistoneMethylation
Changes during Lineage Restriction
Genes with increased expression in the luminal progenitor rela-
tive to the MaSC/basal subset tended to show increased
H3K4me3 and decreased H3K27me3 marking, whereas genesFigure 2. Histone Methylation Profiles across Key MaSC-Enriched and
(A and B) Scatter plots show that expression changes for the 500 most DE gen
correlated with H3K27me3 (bottom panels) (p < 106).
(C) Read coverage graphs for H3K4me3 (red) and H3K27me3 (blue) in each epith
luminal progenitor-specific genes. Y-axes show fragments per million on the sca
samples; error bars show SEM.
See also Figure S1 and Table S1.
Cwith decreased expression showed the opposite epigenetic
changes (Figures 1C and 2A). The same was true of genes differ-
entially expressed in the mature luminal versus the luminal
progenitor subset (Figures 1C and 2B). This shows that histone
methylation is dynamically associated with gene expression
during lineage restriction and is likely to be a key mediator of
expression changes that direct basal to luminal cell-fate switch-
ing and luminal maturation. Illustrative read coverage graphs of
H3K4me3 and H3K27me3 patterns across genes characteristic
of the MaSC/basal (snai2, cytokeratin 5, and Trp63) and luminal
progenitor subsets (c-kit, Elf-5, and Hey2) are shown in Fig-
ure 2C. Histone modifications in the TSS regions were verified
for a number of candidates using ChIP combined with quantita-
tive RT-PCR (Figure 2C).
Hormonal Changes Drive Global Mammary Epigenetic
Alterations
Since hormone deprivation and pregnancy drastically alter
MaSC numbers and the gene expression profiles of different
epithelial subtypes (Asselin-Labat et al., 2010), we investigated
whether histone methylation is a regulator of these changes.
ChIP-seq profiles were generated of H3K4me3 and H3K27me3
marks in the MaSC/basal and luminal populations from the
glands of ovariectomized or midpregnant (12.5 days) mice as
well as from control virgin mice. The total luminal subset
(CD29loCD24+) was used, given that the CD61+ progenitor pop-
ulation declines precipitously during pregnancy (Asselin-Labat
et al., 2007). Expression changes in ovariectomized mice were
limited to a few dozen genes (15 differentially expressed genes
in the MaSC/basal subset and 82 genes in luminal cells at
a 5% false discovery rate [FDR]) and were only modestly
correlated with epigenetic changes (Figure 3A). Nevertheless,
changes in the expression of specific genes, such as Arf and
cyclin D2, in the MaSC/basal population correlated with
changes in H3K27me3 occupancy at their TSS (Figure S2A).
Cell cycle genes were significantly enriched among differentially
H3K27me3-marked genes in the luminal population upon ovari-
ectomy (p = 0.02), consistent with cell cycle regulators driving
proliferation in response to steroid hormones.
A more global function for H3K27 trimethylation was revealed
in the hormonal milieu of pregnancy that is largely governed by
progesterone and prolactin. Most noticeably, a strong inverse
relationship was apparent between H3K27me3 marking and
expression changes in the luminal cells of pregnant mice (Fig-
ure 3B). Key luminal genes required for differentiation and
concomitant milk production and upregulated in pregnancy
(Elf-5, Wap, and Csn2) showed strongly decreased H3K27me3
modifications that were confirmed by ChIP-quantitative RT-
PCR (qRT-PCR) analysis (Figure 3C). Conversely, luminal genes
expressed in the steady-state gland but downregulated duringLuminal Progenitor Genes
es are directly correlated with H3K4me3 changes (top panels) and inversely
elial subset 10 kb ± of the TSS region of three MaSC/basal-specific and three
le 0–10. Bar plots show ChIP qRT-PCR data for three independent biological
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Figure 3. The Mammary Epithelial Epigenome Is Influenced by Hormonal Status
(A and B) Scatter plots of expression versus epigenetic log2-fold changes in the mammary epithelial subsets of (A) ovariectomized mice and (B) pregnant mice.
Increased H3K27me3 marking strongly mediates decreased expression in luminal cells from 12.5 day pregnant glands (p < 106). Other correlations were also
significant (p < 0.05), except H3K27me3 modifications in the MaSC subset at midpregnancy.
(C) Derepression of milk genes and Elf-5 in the luminal subset of pregnant glands at 12.5 days. The left panel shows read coverage of H3K27me3 marks around
the TSS of each gene. The right panel shows ChIP-qRT-PCR confirmation (n = 3; error bars show SEM).
(D) Repression of luminal commitment genes (Wnt7b, Foxa1, and Hey1) in the luminal subset during pregnancy correlates with increased H3K27me3 marks. The
left panel shows read coverage for H3K4me3 (red) and H3K27me3 (blue) around the TSS of each gene. The right panel shows ChIP-qRT-PCR confirmation (n = 3;
error bars show SEM).
See also Figure S2, and Tables S1 and S2.
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pregnancy, such as wnt7b, and the luminal commitment genes
Foxa1 (Bernardo et al., 2010) and Hey1 (Bouras et al., 2008)
had abundant H3K27me3 modifications at 12.5 days of
pregnancy, as validated by ChIP-qRT-PCR (Figure 3D). These
changes likely reflect a shift in gene expression within the
emerging alveolar cells toward the highly specialized function
of milk production. In general, genes repressed in pregnancy
with a concomitant increase in H3K27me3 marking were en-
riched for the mammary morphogenesis and developmental
gene categories. Genes upregulated during pregnancy and
with reduced H3K27me3 modifications showed enrichment for
lipid biosynthesis and lipid catabolism (Table S2), commensu-
rate with the changed mammary function during pregnancy.
Although H3K27me3 was not consistently correlated with ex-
pression changes in the MaSC/basal subset of pregnant mice, it
nevertheless appeared to play an important role for specific
genes. In particular, it was associated with derepression of a
number of genes that are normally expressed only in the luminal
lineage. This observation is of particular interest given the
dramatic expansion of theMaSC pool and its altered gene signa-
ture during pregnancy (Asselin-Labat et al., 2010). Quantitative
RT-PCR confirmed expression of the milk protein genes Wap
and Csn2 and the luminal progenitor transcription factor Elf-5,
all of which are normally restricted to luminal subpopulations
(Lim et al., 2010; Figure S2B). Compatible with their derepres-
sion, each of these genes showed diminished H3K27me3 marks
at their TSS during pregnancy, as confirmed by ChIP-qRT-PCR
analysis (Figure S2C). Thus, lineage-priming may occur in the
expanded stem cell population during pregnancy prior to com-
mitment along the alveolar lineage. Intriguingly, expression of
the basal-specific gene Lgr5 was extinguished in the MaSC
pool during pregnancy, accompanied by augmented H3K27 tri-
methylation (Figures S2B and S2C).
At a more global level, the total number of genes within the
luminal subset with significant (FDR< 0.05) H3K27me3modifica-
tions relative to input increased in pregnancy but decreased in
ovariectomized mice significantly (Figure S2D). In summary,
striking epigenetic changes occurred within a specific cellular
subset during pregnancy and were selectively observed for
H3K27me3 but not H3K4me3 or H3K9Ac modifications (data
not shown), which showed small changes.
Dynamic Expression of the Polycomb Group Repressor
Ezh2 in the Mammary Gland
In view of the marked hormone-induced changes in the global
H3K27me3 profile during pregnancy, we examined the ex-
pression of Ezh2 during mammary ontogeny. Ezh2 is the core
enzymatic subunit of PRC2 that catalyzes K27 trimethylation
on H3 (Margueron and Reinberg, 2011) and has emerged as
an important prognostic marker in breast cancer. Western blot
analysis showed that Ezh2 expression was low in virgin glands
and peaked during early to midpregnancy before declining in
late pregnancy (Figure 4A). Interestingly, the profile of total
H3K27me3-modified protein closely mirrored that of Ezh2 (Fig-
ure 4A). Immunohistochemical staining confirmed the ex-
pression of Ezh2 during mammary morphogenesis and further
revealed that it was abundant in the terminal end buds (TEBs)
of the developing pubertal gland, with lower levels visible in theCnuclei of myoepithelial and luminal cells of mature ducts (Fig-
ure 4B). Ezh2 staining was most intense in the ducts and alveoli
during pregnancy (Figure 4B) and declined to low levels in
lactating and involuting glands (Figure 4B).
Ezh2 Deficiency Delays Mammary Morphogenesis
during Puberty
To investigate the physiological role of Ezh2 in the mammary
gland, we conditionally targeted the Ezh2 locus using cre recom-
binase driven by the mouse mammary tumor virus (MMTV)
promoter. Fluorescence-activated cell sorting (FACS) analysis
of reporter mice demonstrated that the MMTV promoter is active
in both luminal and basal mammary epithelial cells (Figure S3A)
but not in the stroma (<0.05% cells). Immunohistochemistry
and western blot analysis confirmed efficient deletion of Ezh2
in MMTV-cre;Ezh2f/f glands (Figures 4A and 4C). Its deletion
markedly impaired elongation and branching of the mammary
epithelial tree during puberty (n = 6), resulting inmarkedly smaller
ductal trees in young adult mice (n = 14) relative to control age-
matched glands (n > 40) from either MMTV-cre;Ezh2f/+, Ezh2f/f,
or Ezh2f/+ littermates or MMTV-cre mice (Figures 4D and S3B).
The same phenotype was observed on a mixed C57Bl6/FVB/N
or pure FVB/N background. MMTV-cre transgenic females
behaved like wild-typemice and could support large-sized litters
through normal lactation, thus differing from the cre strains
recently described (Robinson and Hennighausen, 2011). The
delay in morphogenesis was also associated with decreased
filling of the fat pad in Ezh2-deficient mice (Figure 4E) and the
persistence of TEBs (Figure S3B). By 12 weeks of age, ductal
morphogenesis of most Ezh2-deficient mammary glands was
partially rescued, presumably through recurrent hormonal stim-
ulation (Figure S3B). Cell fate appeared unaffected by loss of
Ezh2, as assessed by immunostaining for luminal, myoepithelial,
and alveolar markers (K18, K14, p63, and Npt2b) (Figures S3C
and S3D; data not shown).
Ezh2Controls the Activity ofMammary Stem/Progenitor
Cells
A potential role for Ezh2 in regulating MaSC function was next
addressed using the mammary fat pad reconstitution assay.
Limiting dilution assays of freshly sorted CD29hiCD24+ cells re-
vealed a 14-fold decrease in the frequency of mammary repopu-
lating cells in MMTV-cre;Ezh2f/f compared to control mammary
glands (Table 1). This observation indicates that Ezh2 has amajor
role in either stem or descendant progenitor cells. Further delin-
eation of the hierarchy will be required to distinguish between
these possibilities.
The effect of Ezh2 loss on epithelial proliferation was next
assessed by in vivo bromodeoxyuridine (BrdU) labeling. Prolifer-
ative activity was significantly impaired in the TEBs of MMTV-
cre;Ezh2f/f mammary glands compared to MMTV-cre;Ezh2f/+
and Ezh2f/+ control glands (Figures 4F and S3E). Furthermore,
both the MaSC/basal and luminal populations from Ezh2-defi-
cient glands had little clonogenic activity in vitro on fibroblast
feeders, with only small colonies visible (Figure 4G). These
data point to a critical role for Ezh2 in regulating the activity
of multiple progenitor cell types in the mammary gland. It
seems likely that the developmental defect in MMTV-cre;Ezh2f/fell Reports 3, 411–426, February 21, 2013 ª2013 The Authors 417
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Table 1. Limiting Dilution Analysis of theMammary Repopulating
Frequency of CD29hiCD24+ Cells Isolated from YoungMMTV-cre;
Ezh2f/f or Control Glands
Number of CD29hiCD24+ Cells
Injected per Mammary Fat Pad
Number of Positive Outgrowthsa
Ezh2f/+ MMTV-cre; Ezh2f/f
100 5/8
200 2/5 0/6
400 11/16 0/10
800 4/7 1/17
1,600 5/6 1/5
3,200 9/12
6,000 2/7
Repopulating frequency 1/460 1/6,419
(95% confidence interval): (1/722–1/293) (1/11,188–1/3,683)
p value <0.00001
CD29hiCD24+ cells frommammary glands of 8- to 9-week-old mice were
injected into the cleared mammary fat pads of 3-week-old nonobese dia-
betic-severe combined immunodeficient female recipients. Data are
pooled from three independent experiments collected 8 weeks post-
transplantation. The repopulation frequency was calculated using limiting
dilution analysis as described (Hu and Smyth, 2009).
aShown as number of outgrowths per number of injected cleared
mammary fat pads.mammary glands manifests in puberty, because this stage
requires large numbers of progenitor cells to orchestrate ductal
growth (Asselin-Labat et al., 2007).
Loss of Ezh2 Profoundly Affects the Expression of Cell
Cycle and Epidermal Genes
To identify potential downstream effectors of Ezh2, the genome-
wide transcriptional profiles of the MaSC/basal and luminal pop-
ulations in their steady state were determined following ex vivo
cre-mediated excision of Ezh2. Similar to freshly sorted cells
(Figure 4G), the clonogenic capacity of these Ezh2-deficient
MaSC/basal and luminal populations was dramatically reduced
compared to control cultures (Figure S4A). Gene ontology anal-
ysis of the top 500 differentially expressed genes revealed a sig-
nificant association with cell cycle, DNA replication, and DNAFigure 4. Ezh2 Is Required for Normal Mammary Gland Development
(A) Western blot analysis of mammary gland lysates for expression of Ezh2 and H3
provided the controls.
(B) Immunohistochemical staining of mammary gland tissue sections from FVB
(6 weeks), mature ducts in 8-week-old mice; alveoli in early pregnancy (6.5 d
bars, 50 mm.
(C) Immunohistochemical staining of TEBs for Ezh2 expression in MMTV–cre; Ez
(D) Whole-mounts of mammary glands from 7-week-old virgin MMTV–cre; Ezh2f/f
lymph node in the inguinal gland is marked by a white arrow. Scale bars, 2.0 mm
(E) Extent of fat pad filling was estimated in virgin mice at 6, 7, and 8 weeks of a
(F) Immunohistochemical staining of terminal end buds for BrdU incorporation, s
glands compared to those from Ezh2f/+ and MMTV–cre; Ezh2f/+ mice. Scale bar
(G) Colony-forming capacity of sorted MaSC-enriched (CD29hiCD24+; labeled C
fibroblast feeders from 8-week-old MMTV–cre; Ezh2f/f mice compared to Ezh2f
CD61+ luminal progenitors that could be isolated from the smaller targeted gland
quantitation of the colony forming capacity of the CD29loCD24+ and CD29hiCD2
represent mean ± SD of three independent experiments, with eight replicates fo
See also Figure S3.
Crepair (Figure S4B). Of the top ranked genes, three potent cell
cycle inhibitors were derepressed: Cdkn1c (p57), Cdkn2a
(Ink4a/Arf), and Cdkn1a (p21). Consistent with Arf being an
important target of Ezh2, Arf transcript levels were considerably
lower in the luminal population from pregnant glands than in
other subsets and Arfwas derepressed in Ezh2-deficient luminal
cells at midpregnancy (Figure S4C). Gene expression changes in
Ezh2-deficient cells were inversely correlated with changes in
pregnancy (Asselin-Labat et al., 2010), with 67% (52 of 78) of
differentially expressed genes in the MaSC/basal subset and
91% (146 of 160) in the luminal subset showing changes in oppo-
site directions.
Interestingly, one of the top derepressed gene sets in the
MaSC/basal population, other than those related to cell cycle
regulation, was keratinocyte differentiation (Figure S4B). The
expression of genes within the epidermal differentiation complex
on mouse chromosome 3, previously shown to be a target of
Ezh2 repression in skin (Ezhkova et al., 2009), was activated in
the MaSC-enriched subset from Ezh2-deficient glands. This is
consistent with previous reports of misexpression of nonlineage
genes associated with Ezh2 deletion (see Discussion). To inves-
tigate a potential relationship between the gene expression sig-
natures of Ezh2-deficient cells and metaplastic breast cancers,
the molecular profiles of the different breast cancer subtypes
were interrogated with the Ezh2-deficient MaSC/basal cell
signature. Intriguingly, this signature was found to bemost highly
represented in the claudin-low subgroup based on signature ex-
pression scores (Figure S4D). The claudin-low subtype exhibits
metaplastic features, expresses lower levels of Ezh2 than the
other subtypes, and can even display epidermal traits (Keller
et al., 2012), suggesting that they have undergone metaplasia
as a result of aberrant differentiation.
Ezh2 Deficiency Leads to Reduced Alveolar
Development and Failure of Lactation
We next examined the effect of Ezh2 deficiency on pregnancy
and lactation. Although alveoli formed in MMTV-cre;Ezh2f/f
mammary glands during pregnancy (Figure 5A), they were fewer
and more disorganized than those in Ezh2f/+, Ezh2f/f, or MMTV-
cre mammary glands (Figure 5B; data not shown). This pheno-
type appeared most obvious from midpregnancy (n = 9), whereK27me3 protein during development. Ezh2 cKO tissue (12.5 dP) and antitubulin
/N females for Ezh2 expression, representing TEBs that characterize puberty
P) and midpregnancy (12.5 dP); lactation (1 dL); and involution (4 dI). Scale
h2f/f mice compared to littermate Ezh2f/+ glands. Scale bars, 50 mm.
mice compared to glands from Ezh2f/+ and MMTV-cre; Ezh2f/+ littermates. The
.
ge using ImageJ software, with four to nine mice for each time point.
howing reduced numbers of proliferating cells in MMTV–cre; Ezh2f/f mammary
s, 50 mm. Isotype control antibody panels are shown in insets.
D29hi) and luminal cells (CD29loCD24+; labeled CD29lo) grown on irradiated
/+ littermates. The same results were obtained for 6-week-old mice. The few
s also had reduced clonogenic activity (data not shown). Histogram showing
4+ subpopulations (200 and 300 cells were plated per well, respectively). Data
r each. *t test p < 0.0001 compared to Ezh2f/+ controls for both subsets.
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Figure 5. Ezh2 Deficiency Leads to Abnormal Alveolar Development
(A) Whole-mounts of mammary glands from MMTV–cre; Ezh2f/f mice (right panel) compared to those from Ezh2f/+ and MMTV–cre; Ezh2f/+ mice at day 12.5 of
pregnancy show retardation of ductal growth. Mice were mated at 7 weeks of age. No gross abnormalities in the alveolar units were evident in early pregnancy
(6.5 dP; data not shown). Scale bars, 4.0 mm.
(B) H&E sections of mammary glands from MMTV–cre;Ezh2f/f, Ezh2f/+ littermates, and MMTV-cre mice at days 12.5 and 16.5 of pregnancy. Scale bars, 50 mm.
(C) Western blot analysis of mammary glands from MMTV-cre; Ezh2f/f and Ezh2f/+ littermate control mice for expression levels of Ezh2, H3K27me3 protein, and
tubulin.
(D) Derepression of cell cycle genes in pregnant glands lacking Ezh2. ChIP-qRT-PCR for H3K27me3 marks across Cdkn2a/Arf, Cdkn1c (p57), Wnt7b, and
Camk2n1 in the expanding luminal population from day 12.5 pregnant mice. Histograms show the mean of two independent samples with at least two technical
replicates for each.
(E) Immunostaining for milk protein of MMTV-cre; Ezh2f/f tissue sections (right panel) compared to an Ezh2f/+ littermate control at 16.5 days of pregnancy (left
panel). Scale bars, 100 mm.
See also Figures S3 and S4.ductal elongation of the mammary tree remained stunted in 50%
of Ezh2-deficient glands (Figure 5A). Heterozygotes seemed to
have an intermediate phenotype, with less dense but apparently
normal alveoli (Figures 5A and S3F). Notably, progenitor cell
activity was severely compromised in all three epithelial subsets
isolated frommidpregnant Ezh2-deficient mammary glands (Fig-
ure S5). Western blot analysis confirmed loss of Ezh2 in these
glands and showed a pronounced decrease in H3K27me3
protein in Ezh2-deficient glands in either the pregnant (Figure 5C)
or virgin state (Figure S5D). The residual level of H3K27me3
protein in targeted glands may reflect low levels of Ezh2 de-
tectable in MMTV-cre;Ezh2f/f mammary glands but also sug-
gests that other methylases contribute to H3K27 trimethylation.
Importantly, ChIP combined with qRT-PCR confirmed that the420 Cell Reports 3, 411–426, February 21, 2013 ª2013 The Authorscell cycle inhibitors Arf and p57 (Cdkn1c) were derepressed in
primary Ezh2-deficient epithelial cells at midpregnancy (Fig-
ure 5D), as well as other genes abundantly marked by
H3K27me3 at this time-point, including Wnt7b and Camk2n1.
Overall, these data indicate that Ezh2 plays an important role
in the methylation of H3K27 in mammary epithelial cells.
Milk production was readily detectable in MMTV-cre;Ezh2f/f
glands at 16.5 days of pregnancy, suggesting that Ezh2 does
not affect alveolar differentiation (Figure 5E). However, lactation
was severely compromised (n = 4), resulting in all pups dying
within 2 or 3 days of birth. Concordantly, Ezh2-deficient mam-
mary glands showed grossly abnormal morphology at day two
of lactation, relative to control glands that underwent normal
lactation (Figure S3G). This phenotype is likely to result from
a decrease in alveologenesis rather than differentiation, reflect-
ing the critical role of Ezh2 in regulating progenitor cell activity.
Progesterone-Mediated Regulation of Ezh2 Expression
We explored whether posttranscriptional control mechanisms
contributed to augmented Ezh2 expression during pregnancy,
since only a modest increase in Ezh2 transcript levels was evi-
dent in epithelial subsets from midpregnant glands (Asselin-
Labat et al., 2010). Ezh2 has been shown to be phosphorylated
on multiple residues, including serine 21 and threonine residues
345 and 487 (reviewed in Caretti et al., 2011). Western blot
analysis using phosphospecific antibodies revealed a striking
increase in the level of phosphorylated Ezh2 on Thr487 in early
tomidpregnancy (Figure 6A). Little or no change in the phosphor-
ylation of Ser21 or Thr345 was detected (data not shown). Inter-
estingly, expression of the cell cycle-dependent kinases Cdk1
and Cdk2, which have been demonstrated to phosphorylate
Ezh2 on threonine residues, mimicked that of Ezh2 and phos-
pho-Ezh2 (Figure 6A). Hence, it is plausible that phosphorylation
of Thr487, perhaps byCdk1 or Cdk2, activates or stabilizes Ezh2.
To investigate a more direct role for pregnancy hormones in
regulating Ezh2 and its phosphorylation, we treated mice in vivo
with progesterone or the peptide hormone prolactin that con-
tribute to the formation and differentiation of alveoli during
pregnancy (Oakes et al., 2008). It is noteworthy that PR levels
follow a similar pattern to that of Ezh2 and phospho-Ezh2, in
part reflecting epithelial content (Figure 6B). Analysis of mam-
mary glands following hormonal treatment showed that phos-
phorylated Ezh2 (Thr487) increased with progesterone but not
prolactin (Figure 6C). At 72 hr after progesterone treatment,
phospho-Ezh2 and Cdk1 were both substantially elevated (Fig-
ure 6D). Moreover, knockdown of PR in T-47D breast cancer
cells was accompanied by a decrease in Ezh2 and phospho-
Ezh2 levels (Figure 6E), suggesting that both transcriptional
and posttranslational mechanisms contribute.
To further examine the effects of progesterone on Ezh2 ex-
pression in different cellular compartments, we isolated discrete
subtypes of luminal progenitor cells that differ in their hormone
receptor status through the use of anti-CD49b and Sca-1 anti-
bodies (Li et al., 2009; Figure S6). Quantitative RT-PCR analysis
showed that the hormone receptor (HR)+ and HR progenitor
populations contained cells highly enriched for PR+ and PR
cells (Figure 6F). Interestingly, progesterone strongly induced
Ezh2 in the PR subset, indicating a paracrine mode of stimula-
tion (Figure 6G). Conversely, Ezh1 expression was not induced
by progesterone (data not shown). As Rankl is a known target
of PR, we evaluated the expression of Rankl and the Rank
receptor in the three luminal subsets. Rankl was most highly
induced by progesterone in mature PR-positive ductal cells
(CD24+CD29loCD49bSca-1+), whereas Rank was abundantly
expressed in PR luminal progenitor cells, suggesting that the
Rankl/Rank axis is an important paracrine mediator of proges-
terone-induced Ezh2 expression.
DISCUSSION
The epigenome is presumed to play a critical role in adult stem
cells and their progressive commitment to differentiated cells.CIndeed, elucidation of the genome-wide histone methylation
profiles of distinct mammary epithelial subtypes revealed that
H3K27me3-mediated epigenetic silencing is a key determinant
of gene expression during lineage restriction in the steady-state
mammary gland. Moreover, we found that pregnancy hormones
triggered striking genome-wide changes in H3K27me3 chro-
matin modifications in the expanding alveolar cell population.
Our elucidation of the physiological role of Ezh2 in controlling
mammary progenitor activity and alveolar development provides
direct evidence that this histone methylase has a critical role in
coordinating changes in the epigenome with regulatory gene
networks in response to hormonal stimuli.
The H3K4 and H3K27 trimethylated ‘‘landscapes’’ of the
mammary epithelium are highly dynamic in the steady-state
gland. Chromatin analyses combined with expression profiling
showed that these histone modifications tightly correlated with
transcriptional activity. In particular, H3K27me3 modifications
increased profoundly upon restriction of the MaSC/basal popu-
lation to the luminal lineage, suggesting that it contributes to
gene expression changes during lineage restriction. Histone
and DNA methylation patterns have been addressed in human
breast epithelial cells (CD44+ and CD24+), but these are not
directly comparable to the three cellular subsets defined in the
mouse mammary gland (Maruyama et al., 2011). Pertinently,
in another ectodermal lineage, the transition from activated
skin stem cells to committed transit amplifying cells involves
K27me3-PcG-mediated repression of stem cell genes and dere-
pression of PcG-silenced regulators (Lien et al., 2011). Given that
the MaSC/basal subset is heterogeneous at the cellular level,
although remarkably similar at the gene expression level (Stingl
et al., 2006; unpublished data), it remains unclear whether the
observed epigenetic changes in this population reflect those
occurring in MaSCs. The proportion of genes exhibiting bivalent
marks at their TSS also increased with restriction along the hier-
archy, with lowest levels in theMaSC/basal cell subset. It is inter-
esting to note that hair follicle stem cells contain few bivalent
marks (Lien et al., 2011).
Steroid hormones profoundly influence the mammary epige-
nome. Modulation of hormone levels via ovariectomy, preg-
nancy, or treatment with antiestrogen inhibitors strongly affects
both MaSCs and the luminal cell compartment (Asselin-Labat
et al., 2010). Hormone deprivation only modestly changed
H3K4me3 and H3K27me3 marking in both the stem cell-en-
riched and luminal populations, implying that other epigenetic
mechanisms may contribute to changes in gene expression.
However, the changes apparent in cell cycle regulators may
suffice to drive MaSCs into a more quiescent state, as indicated
by molecular profiling and cellular analyses (Asselin-Labat et al.,
2010). On the other hand, a striking role for H3K27me3
modifications was revealed during pregnancy, specifically in
the expanding alveolar luminal subset. In that subset, there
was a dramatic increase in the number of genes marked by
H3K27me3. Moreover, Ezh2 and H3K27-trimethylated protein
levels mirrored each other during mammary gland develop-
ment, with highest levels in early to midpregnancy, returning
to low levels in the late stages of pregnancy. In parallel, a
decrease in H3K27me3 marks has been observed during the
differentiation of keratinocytes (Sen et al., 2008), neuronal cellsell Reports 3, 411–426, February 21, 2013 ª2013 The Authors 421
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Figure 6. Pregnancy Hormones Induce Phosphorylation of Ezh2 and Expression of Cdk-1/2, with Progesterone as an Important Mediator
(A) Western blot analysis of whole gland cell lysates for total Ezh2, phospho-Ezh2(Thr 487), Cdk1, and Cdk2 during mammary gland development. dP, days
pregnancy; cKO corresponds to MMTV-cre;Ezh2f/f at 12.5 dP. Antitubulin provided the loading control.
(legend continued on next page)
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(Mikkelsen et al., 2007), and skeletal muscle (Caretti et al.,
2004).
Our findings indicate that upregulation of Ezh2 in pregnancy is
a key event that coordinates changes in the chromatin land-
scape with modulation of gene expression. The critical role of
Ezh2 in governing the activity of progenitor cells appears to
underlie its requirement for driving expansion of the alveolar
cell compartment. Notably, Ezh2 deficiency in the mammary
gland led to a global decrease in H3K27me3 levels in pregnancy,
indicating that it is a key methyl-transferase for H3K27. Ezh1
and/or demethylases may also contribute to the overall level of
H3K27me3 protein in the mammary epithelia. It is noteworthy
that targeted deletion of Eed, which is required for the function
of both Ezh1 and Ezh2, yielded a similar phenotype to that
following Ezh2 ablation (S. Orkin, K.B., and J.E.V., unpublished
data).
Ezh2 is also essential for the activity of basal and luminal
progenitor cells in the mammary gland during puberty. In Ezh2-
deficient mice, mammary morphogenesis was severely compro-
mised but could be effectively rescued through recurrent estrus
cycling by 15 weeks of age. Notably, mammary repopulating
activity was reduced 14-fold upon loss of Ezh2. Whether this
reflects a defect in the stem cell itself or in bipotent or committed
progenitor cells is uncertain. Pertinently, Ezh2-deficient progen-
itor cells in the MaSC/basal and luminal subsets had almost no
clonogenic activity in vitro. The cell cycle GO groups were
substantially affected by Ezh2 loss, consistent with Ezh2 func-
tioning as a silencer of cell cycle inhibitors in progenitor cells
and thus preventing exit from the cell cycle. Indeed, targeted
disruption of Ezh2 has demonstrated that it is required for the
proliferation of myogenic and skin basal progenitors, in part
due to repression of the Ink4a/Arf locus in the skin (Ezhkova
et al., 2009) and Ink4a in muscle stem cells (Juan et al., 2011).
The Ink4a/Arf locus is also likely to be a key mediator of Ezh2-
dependent cell cycle regulation in mammary progenitor cells,
given the reciprocal expression of Ezh2 and Arf. As a regulator
of proliferation, Ezh2 also plays an essential role in lymphopoie-
sis (Su et al., 2003), adipogenesis (Wang et al., 2010), postnatal
cardiac homeostasis (Delgado-Olguı´n et al., 2012), and hair
follicle morphogenesis in adult skin (Ezhkova et al., 2011). In
the latter case, however, targeted deletion of both Ezh1 and
Ezh2 was required to perturb hair follicle homeostasis.
Cell-fate decisions and differentiation in the mammary epithe-
lium do not appear to require Ezh2. Its absence did not affect(B) Western blot analysis of PR and Ezh2 expression in whole mammary gland ly
(C) Western blot analysis of phospho-Ezh2(Thr 487) expression in whole gland lys
for 16 hr. No induction by prolactin was observed 24 hr posttreatment (data not
(D) Western blot analysis of total Ezh2, phospho-Ezh2(Thr 487), and Cdk1 express
(E) Knockdown of PR in human T-47D cells using small interfering RNAs (siRNAs)
Western blot analysis of PR, Ezh2, phospho-Ezh2(T487), and tubulin expression
(F) Quantitative RT-PCR analysis of PR expression in steady-state populations
Sca-1+) and hormone receptor-negative luminal progenitor (CD24+CD29loCD49
CD29, CD24, Sca1, and CD49b, as in Figure S6. n = 3 independent experiments
(G) Quantitative RT-PCR analysis of Ezh2, Rank, and Rankl expression in mature l
vehicle for 48 hr (n = 3; error bars show SEM). Note the induction of Ezh2 in the
(H) Schematic model of the role of progesterone in coordinating changes in the e
during pregnancy. Continual exposure to progesterone is hypothesized to result
See also Figures S5 and S6.
Cexpression of mammary lineage markers, including alveolar
markers, and those required for milk synthesis. Although Ezh2-
deficient glands could produce milk, lactation failed due to the
low density of alveolar units. Furthermore, Ezh2 levels decline
precipitously in late pregnancy and lactation when terminal
differentiation occurs. Indeed, downregulation of Ezh2 prior to
lactation (when progesterone levels fall) may serve as a switch
to mediate derepression of genes required for lactogenesis (Ru-
dolph et al., 2003), including lipid biosynthesis genes, as sug-
gested by our bioinformatic analysis. The role of Ezh2 is thus
distinct from that of the polycomb family member Bmi1, which
represses alveolar differentiation in the adult mammary gland
(Pietersen et al., 2008a). However, polycomb-mediated repres-
sion of broad lineage determination programs can prevent the
activation of ‘‘extraneous’’ differentiation networks. Expression
profiling of Ezh2-deficient epithelial cells revealed inappropriate
expression of genes within the epidermal differentiation complex
(EDC), which is normally expressed in keratinocytes. The EDC
comprises six late-differentiation genes, including involucrin.
Interestingly, increased numbers of involucrin-positive luminal
cells appeared in Ezh2-deficient glands compared to control
glands (data not shown). Thus, Ezh2 normally represses expres-
sion of EDC genes in the mammary epithelium. In parallel, non-
skin lineage genes are also silenced in hair stem cells by
H3K27me3 (Ezhkova et al., 2011; Lien et al., 2011), and unsched-
uled expression of nonmyogenic lineage genes has been ob-
served in Ezh2-null skeletal muscle (Juan et al., 2011).
Ezh2 phosphorylation may be an important mechanism
by which hormones influence mammary epithelial expansion
during pregnancy. Phosphorylation of Ezh2 on threonine resi-
due 487 and levels of the cell cycle kinases Cdk1 and Cdk2
increased markedly during pregnancy, mimicking the pattern
for H3K27me3 protein. Both Cdk1 and Cdk2 can phosphorylate
Ezh2, and Cdk1 is positively associated with cell proliferation
(Malumbres and Barbacid, 2009). Furthermore, Cdk-mediated
phosphorylation of Ezh2 during cell cycle progression has
emerged as an important mechanism regulating Ezh2 function.
Thr345-phosphorylated Ezh2 appears to orchestrate epigenetic
silencing by promoting the recruitment of PRC2 to Ezh2 targets
(Chen et al., 2010; Kaneko et al., 2010). However, the role of Ezh2
phosphorylation on Thr487 remains unclear, since Thr487 phos-
phorylation impaired Ezh2 methyltransferase activity in one
study (Wei et al., 2011) but did not correlate with Ezh2 loading
at target genes in two other studies (Kaneko et al., 2010; Wusates from mice at different developmental time points.
ates from mice treated in vivo with progesterone (Pg), prolactin (Prl), or vehicle
shown). Tubulin provided a loading control.
ion in whole gland lysates frommice treated in vivo with Pg or vehicle for 72 hr.
. Cells were transfected with siGenome Smartpools for RISC-free, PR, or Ezh2.
was performed 60 hr following transfection.
of ML, hormone receptor-positive luminal progenitor (CD24+CD29loCD49b+
b+Sca-1). Lineage-negative cells were fractionated using a combination of
; error bars show SEM.
uminal and progenitor subsets isolated from mice treated with progesterone or
PR LP subset.
pigenome with gene expression changes in the alveolar luminal compartment
in epigenetic changes that culminate in breast cancer.
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and Zhang, 2011). Our data suggest that Thr487 phosphorylation
is more likely to promote Ezh2 methyltransferase activity in the
mammary gland, since K27-trimethylated H3, total Ezh2, and
phospho-Ezh2 levels were tightly correlated in pregnancy.
Progesterone appears to regulate Ezh2 through different
mechanisms. Acute treatment of mice with progesterone but
not prolactin led to a striking elevation in total Ezh2 and phos-
phorylated protein, suggesting that progesterone influences
the epigenetic ‘‘landscape’’ in pregnancy through modulating
the level of Ezh2 and its activity. Notably, the upregulation of
Ezh2 transcript levels occurred predominantly in the PR-nega-
tive luminal progenitor subset, implying a paracrine regulatory
mechanism. The Rank-Rankl signaling axis emerged as a likely
paracrine mediator, as the progesterone-target Ranklwas highly
induced in mature luminal cells, while Rank was most abundant
in PR-negative progenitors, in which Ezh2 expression was pro-
foundly stimulated. The Rank pathway has also been implicated
in paracrine signaling toMaSCs (Asselin-Labat et al., 2010; Joshi
et al., 2010). The dynamic expression pattern of phosphorylated
(T487) Ezh2 protein during mammary ontogeny suggests that
posttranslational mechanisms also regulate Ezh2 activity. In-
deed, it is tempting to speculate that Cdk1 (or 2)-mediated phos-
phorylation of Ezh2 is an important mechanism for integrating
cues from progesterone with chromatin modifications in order
to regulate the balance between proliferation and differentiation
in the developing gland (Figure 6H). Progesterone may also
directly influence cell cycle progression by receptor-mediated
recruitment of the cyclin A/Cdk2 complex to progesterone-
responsive promoters (Narayanan et al., 2005). Interestingly,
phosphorylation-mediated repression by Ezh2 occurs in a cell
stage-specific manner during the differentiation of satellite cells
to myotubes in response to signals from regenerating muscle
(Palacios et al., 2010).
Overexpression of EZH2 is a marker of poor prognosis and
metastatic disease in many solid carcinomas, including breast
(Bachmann et al., 2006; Bracken et al., 2003; Kleer et al., 2003;
Pietersen et al., 2008b; Raaphorst et al., 2003) and prostate
(Varambally et al., 2008), both of which are hormone-associated
malignancies. Notably, BRCA1-associated basal-like breast
tumors are selectively dependent on high levels of EZH2, thus
rendering them sensitive to the small molecule inhibitor DZNep
(Puppe et al., 2009). Moreover, EZH2 promotes the expansion
of breast tumor-initiating cells, possibly through the repression
of DNA damage repair pathways (Chang et al., 2011; Zeidler
et al., 2005). EZH2 overexpression is most frequently observed
in basal-like breast cancers. In these cancers, aberrant EZH2
expression may occur early in the oncogenic process and
within luminal progenitor cells that are exposed to sustained
progesterone signaling before they transition to a hormone
receptor-independent state. Interestingly, in utero exposure to
diethylstilbestrol may also influence breast cancer risk through
Ezh2 (Doherty et al., 2010). Our findings that Ezh2 coordinates
signals from progesterone with global changes in the mammary
epigenome have important implications for cancer, given the
impact of ovarian hormones on breast tumorigenesis. Specifi-
cally, the data suggest that sustained hormone exposure may
initiate oncogenesis through dysregulated histone methylation
of chromatin.424 Cell Reports 3, 411–426, February 21, 2013 ª2013 The AuthorsEXPERIMENTAL PROCEDURES
Mouse Strains and Hormone Treatment
Floxed Ezh2 mice were a kind gift from Dr. A. Tarakovsky (Su et al., 2003), and
the MMTV–cre (line A) mice were a gift from K.-U. Wagner (Eppley Institute,
Omaha, NE). MMTV-cre mice were maintained as a pure strain on a FVB/N
background. Floxed or deleted Ezh2 mice were analyzed on either a FVB/N
or mixed FVB/N C57/Bl6 background. For in vivo hormonal treatment,
8-week-old FVB/N female mice were injected intrascapularly daily with 1 mg
progesterone in 200 ml peanut oil or vehicle alone for either 16 or 72 hr or
prolactin (12.5 mg/kg) intraperitoneally for 16 hr. Prolactin (gift from the
National Hormone and Peptide Program, NIDDK) was dissolved at 1 mg/ml
in 0.1% BSA in PBS. The inguinal mammary glands (minus lymph node)
were harvested and snap-frozen. All animal experiments conform to regulatory
standards and were approved by the Walter and Eliza Hall Institute Animal
Ethics Committee.
Mammary Cell Preparation, Cell Sorting, and Transplantation
Mammary epithelial cell suspensions from female mice and flow cytometry
were performed as described (Shackleton et al., 2006). Cells sorted by flow
cytometry were manually counted and transplanted at limiting dilution as
described. Whole-mounting of glands, BrdU-labeling, immunohistochemistry,
and western blotting are described in Extended Experimental Procedures.
Cell Culture and Retroviral-Mediated Infection
For primary cell culture, freshly sorted mammary cells were plated on irradi-
ated fibroblast feeder layers (3,000 Rads) on collagen-coated, six-well plates
and infected as described (Bouras et al., 2008).
ChIP Sample Preparation and Sequencing
Freshly sorted cells were crosslinked with 1% paraformaldehyde and the ChIP
assay performed according to themanufacturer’s protocol (Millipore #17-371).
Briefly, cells were lysed and the Diagenode Bioruptor used for chromatin
shearing to a size range of 200 to 400 bp. Sheared chromatin was diluted
and incubated at 4C overnight with antibodies against Histone H3 trimethyl
Lys4 (Millipore #07-473), Histone H3 trimethyl Lys27 (Millipore #07-449),
Histone H3 dimethyl Lys9 (Abcam #ab1220), or mouse isotype control (Milli-
pore #12-371). Immune complexes were handled as per the manufacturer’s
protocol.
Libraries for paired-end sequencing were prepared by GeneWorks
(Adelaide, Australia) using 10 ng ChIP DNA according to the Illumina ChIP-
seq Sample Preparation protocol, revision A, with the following modifications.
Paired-end adapters were substituted for standard genomic adapters and
library amplification (18 cycles) performed using primers PE 1.0 and 2.0.
Size selection for 300 bp DNA was performed prior to amplification. Final
libraries were analyzed using the Agilent Bioanalyzer High Sensitivity DNA
Kit and sequenced on the Illumina Genome Analyzer IIx running SCS 2.8,
generating 35 base paired-end reads using the CASAVA 1.7 analysis pipeline.
The statistical analyses are described in the Extended Experimental Proce-
dures. Sequence data have been submitted to the Gene Expression Omnibus
under accession number GSE43212.
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The GEO database accession number for the ChIP-seq data is GSE43212.
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